Wall Street analyst estimates for Oragenics, Inc. (OGEN): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Oragenics, Inc. (OGEN) is a U.S.-based biotechnology firm primarily focused on creating treatments for infectious diseases. Among its pipeline assets are two vaccine candidates designed to combat the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2): NT-CoV2-1, an intranasal formulation, and Terra CoV-2, an intramuscular option.
Valuation Ratios
| Price / Book | 0.61 |
| EV / EBITDA | 0.22 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $75044 | $65803 | $30110 | $62622 | $22.1M | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -$75044 | -$65803 | -$30110 | -$62622 | -$22.1M | 0 | 0 | 0 | 0 | 0 |
| Research & Development | $4.8M | $3.5M | $6.0M | $12.1M | $22.1M | $10.6M | $10.1M | $15.5M | $4.1M | $2.39B |
| Selling, General & Admin | $3.8M | $3.2M | $4.0M | $3.8M | $4.5M | $5.3M | $4.5M | $5.5M | $6.4M | $6.97B |
| Operating Expenses | $8.5M | $6.7M | $10.0M | $15.9M | $4.5M | $15.8M | $14.4M | $20.9M | $10.6M | $9.4M |
| Operating Income | -$8.5M | -$6.7M | -$10.0M | -$15.9M | -$26.6M | -$15.8M | -$14.4M | -$20.9M | -$10.6M | -$9.4M |
| EBITDA | -$8.4M | -$6.4M | -$9.9M | -$15.5M | -$26.6M | -$15.7M | -$14.2M | -$20.6M | -$10.5M | $762.2M |
| Interest Expense | $4116 | $216328 | $5786 | $7300 | $10685 | $15756 | $15103 | $30591 | $29828 | $785930 |
| Pre-tax Income | -$8.5M | -$6.7M | -$9.9M | -$15.6M | -$26.4M | -$15.7M | -$14.3M | -$20.7M | -$10.6M | -$10.0M |
| Income Tax | 0 | $13207 | -$79999 | $7756 | 0 | 0 | 0 | 0 | 0 | -$136910 |
| Net Income | -$7.0M | -$6.7M | -$9.9M | -$15.6M | -$26.4M | -$15.7M | -$14.3M | -$20.7M | -$10.6M | -$9.8M |
| EPS | $-94.35 | $-81.99 | $-45.62 | $-22.10 | $-28.05 | $-8.09 | $-7.11 | $-9.18 | $-1.60 | $-4.56 |
| EPS (Diluted) | $-94.33 | $-81.99 | $-45.62 | $-22.10 | $-28.05 | $-8.09 | $-7.11 | $-9.18 | $-1.60 | $-4.56 |
| Shares Outstanding (Diluted) | $74348 | $82104 | $217318 | $704732 | $942187 | $1.9M | $2.0M | $2.2M | $6.6M | $2.2M |
Price
| Price | $0.50 |
| Market Cap | $2M |
| Exchange | AMEX |
| Country | US |
Related companies: AIM · CANF · CNSP · ENSC · KALA · KZIA · QLGN
Explore sector: Healthcare · Biotechnology
More sections of OGEN: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks